Difference between revisions of "Template:SUIT FNS"
(Undo revision 169098 by Gnaiger Erich (talk)) |
|||
Line 1: | Line 1: | ||
Respiratory stimulation by simultaneous action of [[fatty acid]] (F), [[NADH Electron transfer-pathway state |type N substrates]] (N), and [[succinate]] (S), with convergent electron flow in the [[FNS]]-pathway (CETF<small>&</small>CI<small>&</small>II-linked pathway to the Q-junction) for reconstitution of TCA cycle function and additive or inhibitory effect of F. | Respiratory stimulation by simultaneous action of [[fatty acid]] (F), [[NADH Electron transfer-pathway state |type N substrates]] (N), and [[succinate]] (S), with convergent electron flow in the [[FNS]]-pathway (CETF<small>&</small>CI<small>&</small>II-linked pathway to the Q-junction) for reconstitution of TCA cycle function and additive or inhibitory effect of F. | ||
[[File:1OctM;2D;3G;4P;5S;6U;7Rot-.png|300px]] | |||
{| class="wikitable" border="1" | |||
{{Template:SUIT header}} | |||
|- | |||
| 1OctM | |||
| [[OctM]]<sub>''L''</sub> | |||
| [[F]] | |||
| CETF | |||
| OctM<sub>''L''</sub> or PalM: Palmitoylcarnitine & malate, F-LEAK respiration, F<sub>''L''</sub> | |||
{{Template:SUIT F}} {{Template:SUIT L n}} | |||
|- | |||
| 2D | |||
| [[OctM]]<sub>''P''</sub> | |||
| [[F]] | |||
| CETF | |||
| 1OctM;2D | |||
{{Template:SUIT F}} {{Template:SUIT OXPHOS}} | |||
|- | |||
| 2c | |||
| [[OctM]]c<sub>''P''</sub> | |||
| [[F]] | |||
| CETF | |||
| 1OctM;2D;2c | |||
{{Template:SUIT F}} {{Template:SUIT OXPHOS}} {{Template:SUIT c}} | |||
|- | |||
| 3G | |||
| [[OctMG]]<sub>''P''</sub> | |||
| [[FN]] | |||
| CETF&I | |||
| 1OctM;2D;3G | |||
{{Template:SUIT F}} & {{Template:SUIT N}} {{Template:SUIT FN}} {{Template:SUIT OXPHOS}} | |||
|- | |||
| 4P | |||
| [[OctMGP]]<sub>''P''</sub> | |||
| [[FN]] | |||
| CETF&I | |||
| 1OctM;2D;3G;4P | |||
{{Template:SUIT F}} & {{Template:SUIT N}} {{Template:SUIT FN}} {{Template:SUIT OXPHOS}} | |||
|- | |||
| 5S | |||
| [[OctMGPS]]<sub>''P''</sub> | |||
| [[FNS]] | |||
| CETF&CI&II | |||
| 1OctM;2D;3G;4P;3S | |||
{{Template:SUIT F}} & {{Template:SUIT N}} {{Template:SUIT S}} {{Template:SUIT FN}} {{Template:SUIT OXPHOS}} | |||
|- | |||
| 6U | |||
| [[OctMGPS]]<sub>''E''</sub> | |||
| [[FNS]] | |||
| CETF&CI&II | |||
| 1OctM;2D;3G;4P;3S;4U | |||
{Template:SUIT F}} & {{Template:SUIT N}} {{Template:SUIT S}} {{Template:SUIT FN}} {{Template:SUIT U*}} | |||
|- | |||
| 7Rot | |||
| [[S]]<sub>''E''</sub> | |||
| [[S]] | |||
| CII | |||
| 1OctM;2D;3G;4P;3S;4U;5Rot | |||
{{Template:SUIT Rot}} {{Template:SUIT ET}} | |||
|- | |||
| 8Ama | |||
| [[ROX]] | |||
| | |||
|Β | |||
| {{Template:SUIT Ama}} | |||
|} | |||
{{Template:SUIT CIV}} |
Revision as of 14:25, 14 January 2019
Respiratory stimulation by simultaneous action of fatty acid (F), type N substrates (N), and succinate (S), with convergent electron flow in the FNS-pathway (CETF&CI&II-linked pathway to the Q-junction) for reconstitution of TCA cycle function and additive or inhibitory effect of F.
Step | State | Pathway | Q-junction | Comment - Events (E) and Marks (M) |
---|---|---|---|---|
1OctM | OctML | F | CETF | OctML or PalM: Palmitoylcarnitine & malate, F-LEAK respiration, FL
Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration. Template:SUIT L n |
2D | OctMP | F | CETF | 1OctM;2D
Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration. OXPHOS capacity P (with saturating [ADP]), active OXPHOS state. |
2c | OctMcP | F | CETF | 1OctM;2D;2c
Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration. OXPHOS capacity P (with saturating [ADP]), active OXPHOS state. Addition of cytochrome c yields a test for integrity of the mtOM (cytochrome c control efficiency). Stimulation by added cytochrome c would indicate an injury of the mtOM and limitation of respiration in the preceding state without added c due to loss of cytochrome c. Typically, cytochrome c is added immediately after the earliest ADP-activation step (OXPHOS capacity P with saturating [ADP]). |
3G | OctMGP | FN | CETF&I | 1OctM;2D;3G
Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration. & NADH-linked substrates (type N-pathway to Q). Respiratory stimulation by simultaneous action of the F-pathway and N-pathway with convergent electron flow in the FN-pathway for evaluation of an additive or inhibitory effect of F. OXPHOS capacity P (with saturating [ADP]), active OXPHOS state. |
4P | OctMGPP | FN | CETF&I | 1OctM;2D;3G;4P
Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration. & NADH-linked substrates (type N-pathway to Q). Respiratory stimulation by simultaneous action of the F-pathway and N-pathway with convergent electron flow in the FN-pathway for evaluation of an additive or inhibitory effect of F. OXPHOS capacity P (with saturating [ADP]), active OXPHOS state. |
5S | OctMGPSP | FNS | CETF&CI&II | 1OctM;2D;3G;4P;3S
Respiratory stimulation of the FAO-pathway, F, by fatty acid, FA, in the presence of malate, M. Malate is a type N substrate (N), required for the F-pathway. The FA concentration has to be optimized to saturate the F-pathway, without inhibiting or uncoupling respiration. & NADH-linked substrates (type N-pathway to Q). Succinate, S ( type S-pathway to Q). Respiratory stimulation by simultaneous action of the F-pathway and N-pathway with convergent electron flow in the FN-pathway for evaluation of an additive or inhibitory effect of F. OXPHOS capacity P (with saturating [ADP]), active OXPHOS state. |
6U | OctMGPSE | FNS | CETF&CI&II | 1OctM;2D;3G;4P;3S;4U
{Template:SUIT F}} & NADH-linked substrates (type N-pathway to Q). Succinate, S ( type S-pathway to Q). Respiratory stimulation by simultaneous action of the F-pathway and N-pathway with convergent electron flow in the FN-pathway for evaluation of an additive or inhibitory effect of F. Uncoupler titration (avoiding inhibition by high uncoupler concentrations) to obtain electron transfer (ET) capacity E (noncoupled ET-state). Test for limitation of OXPHOS capacity P by the phosphorylation system (ANT, ATP synthase, phosphate transporter) relative to ET capacity E in mt-preparations: E-P control efficiency and E-L coupling efficiency. In living cells: E-R control efficiency and E-L coupling efficiency. |
7Rot | SE | S | CII | 1OctM;2D;3G;4P;3S;4U;5Rot
Succinate pathway control state (S-pathway) after inhibiting CI with rotenone, which also inhibits the F-pathway. Noncoupled electron transfer state, ET state, with ET capacity E. |
8Ama | ROX | Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated after addition of antimycin A (inhibitor of CIII). Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration (mt). |
Step | Respiratory state | Pathway control | ET-Complex | Comment |
---|---|---|---|---|
## AsTm | AsTmE | CIV | CIV | |
## Azd | CHB |